Breaking News Instant updates and real-time market news.

RHHBY

Roche

$0.00

(0.00%)

05:21
10/14/19
10/14
05:21
10/14/19
05:21

Genentech says Phase III PEMPHIX study met primary endpoint

Genentech, a member of the Roche Group, announced data from the Phase III PEMPHIX study evaluating the efficacy and safety of Rituxan compared to mycophenolate mofetil, or MMF, in adults with moderate to severe pemphigus vulgaris, or PV. The study met the primary endpoint at week 52 and demonstrated that Rituxan is superior to MMF, with 40.3% of patients treated with Rituxan achieving sustained complete remission, or CR, without the use of steroids for 16 consecutive weeks or more, compared to 9.5% in the MMF arm. All secondary endpoints were statistically significant in favor of Rituxan: lower cumulative oral corticosteroid dose, fewer flares, a greater likelihood of sustained CR, a lesser likelihood of flare and a greater improvement in the Dermatology Life Quality Index at week 52 compared to the MMF arm. Adverse events were generally consistent with those seen in previous Rituxan clinical studies in PV and other approved autoimmune indications. The study is ongoing, with patients participating in a 48-week safety follow-up period after treatment completion or discontinuation.

  • 04

    Nov

  • 06

    Nov

RHHBY Roche
$0.00

(0.00%)

07/23/19
JPMS
07/23/19
NO CHANGE
JPMS
Neutral
Competition questions for Biogen, Ions' Spinraza not dissipating soon, says JPMorgan
Following Biogen's (BIIB) quarterly results, JPMorgan analyst Jessica Fye notes that while there seems to be limited second quarter impact to the company's and partner Ions Pharmaceuticals' (IONS) Spinraza from Novartis' (NVS) Zolgensma international revenues were down quarter over quarter for a variety of reasons despite double-digit patient growth. Overall, the analyst maintains her view that Roche (RHHBY) and PTC Therapeutics' (PTCT) Risdiplam represents a key potential competitive threat to Spinraza given the convenience of oral dosing and with filing for Risdiplam anticipated in the second half of 2019, in addition to Zolgensma's launch, Fye does not see questions related to competition for Spinraza dissipating anytime soon. The analyst reiterates a Neutral rating on Ions Pharmaceuticals' shares.
07/26/19
UBSW
07/26/19
UPGRADE
UBSW
Buy
Roche upgraded to Buy from Neutral at UBS
UBS analyst Michael Leuchten upgraded Roche to Buy from Neutral and raised his price target for the shares to CHF 300 from CHF 270. The company's legacy portfolio, built around Herceptin and Rituxan, is showing greater resilience while its "credible" neuroscience pipeline is taking shape, Leuchten tells investors in a research note. As such, he now sees Roche's business model as less challenged.
09/13/19
DBAB
09/13/19
NO CHANGE
DBAB
Hold
Novartis' ofatumumab to be 'strong' competitor to Roche drug, says Deutsche Bank
Deutsche Bank analyst Richard Parkes tells investors in a research note after attending the ECTRIMS conference in Stockholm that data from Novartis' (NVS) ASCLEPIOS trials suggests ofatumumab will be a "strong" competitor for Roche's (RHHBY) Ocrevus in relapsing/remitting multiple sclerosis. Parkes says he expects physicians to view the drugs as having broadly comparable and highly compelling efficacy, with ofatumumab's at-home dosing an attractive option for some patients, suggesting meaningful upside potential to his current 2024E ofatumumab sales of $1.1B and possible risks to his forecasts for Roche's Ocrevus. According to physician feedback, Parkes says the drugs are likely to share a rapidly growing market. Parkes maintains a Hold rating and 90 CHF price target on Novartis shares.
09/23/19
GUGG
09/23/19
UPGRADE
Target $403
GUGG
Buy
Guggenheim upgrades Regeneron to Buy, says sentiment too negative
As previously reported, Guggenheim upgraded Regeneron (REGN) to Buy from Neutral as analyst Yatin Suneja noted that Eylea has maintained its dominance in the branded anti-VEGF retinal disease market despite "stiff branded competition" from Roche's (RHHBY) Lucentis and off-label use of Roche's Avastin. Eylea's expansion into new indications has resulted in a diversified business and defensible market position, argued Suneja, who also believes the Street is substantially under-appreciating the market opportunity for Dupixent, which is expected to drive significant leverage in the Sanofi (SNY) antibody collaboration that recently became profitable. Suneja raised the price target on Regeneron shares to $403 from $355.

TODAY'S FREE FLY STORIES

JCP

J.C. Penney

$1.10

0.01 (0.92%)

07:33
11/15/19
11/15
07:33
11/15/19
07:33
Hot Stocks
J.C. Penney expects FY19 adjusted EBITDA to exceed $475M »

In addition, the Company…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

RIGL

Rigel Pharmaceuticals

$2.29

-0.065 (-2.77%)

07:32
11/15/19
11/15
07:32
11/15/19
07:32
Hot Stocks
Rigel Pharmaceuticals receives positive CHMP opinion for fostamatinib »

Rigel Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

JCP

J.C. Penney

$1.10

0.01 (0.92%)

07:32
11/15/19
11/15
07:32
11/15/19
07:32
Hot Stocks
J.C. Penney reports Q3 SSS down 9.3% »

Adjusted comparable store…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

CGC

Canopy Growth

$15.84

-2.68 (-14.47%)

07:32
11/15/19
11/15
07:32
11/15/19
07:32
Recommendations
Canopy Growth analyst commentary  »

Canopy Growth price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

JCP

J.C. Penney

$1.10

0.01 (0.92%)

07:31
11/15/19
11/15
07:31
11/15/19
07:31
Earnings
J.C. Penney reports Q3 adjusted EPS (30c), consensus (55c) »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

ADS

Alliance Data

$106.55

-0.57 (-0.53%)

07:31
11/15/19
11/15
07:31
11/15/19
07:31
Hot Stocks
Alliance Data reports October net charge offs 6.6% vs. 5.3% last month »

Reports October…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMAT

Applied Materials

$56.89

-0.24 (-0.42%)

07:31
11/15/19
11/15
07:31
11/15/19
07:31
Recommendations
Applied Materials analyst commentary  »

Applied Materials price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 09

    Dec

  • 09

    Dec

TORC

resTORbio

$7.93

-0.47 (-5.60%)

07:31
11/15/19
11/15
07:31
11/15/19
07:31
Hot Stocks
Breaking Hot Stocks news story on resTORbio 

resTORbio trading resumes…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FTCH

Farfetch

$7.49

-0.54 (-6.72%)

07:30
11/15/19
11/15
07:30
11/15/19
07:30
Options
Unusual put flow in option market yesterday »

Notable put activity was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WMT

Walmart

$120.65

-0.41 (-0.34%)

07:28
11/15/19
11/15
07:28
11/15/19
07:28
Recommendations
Walmart analyst commentary  »

Walmart price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FTCH

Farfetch

$7.49

-0.54 (-6.72%)

07:26
11/15/19
11/15
07:26
11/15/19
07:26
Recommendations
Farfetch analyst commentary  »

Farfetch price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMRN

Amarin

$21.49

(0.00%)

07:25
11/15/19
11/15
07:25
11/15/19
07:25
Hot Stocks
Breaking Hot Stocks news story on Amarin »

Amarin shares up 21c to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Dec

GLPG

Galapagos

$183.48

-7.74 (-4.05%)

, GILD

Gilead

$63.79

0.46 (0.73%)

07:25
11/15/19
11/15
07:25
11/15/19
07:25
Recommendations
Galapagos, Gilead analyst commentary  »

Galapagos price target…

GLPG

Galapagos

$183.48

-7.74 (-4.05%)

GILD

Gilead

$63.79

0.46 (0.73%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 21

    Feb

VAR

Varian Medical

$125.01

0.45 (0.36%)

07:25
11/15/19
11/15
07:25
11/15/19
07:25
Conference/Events
Varian Medical to host investor day »

Investor day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

OCUL

Ocular Therapeutix

$2.67

-0.1 (-3.61%)

07:23
11/15/19
11/15
07:23
11/15/19
07:23
Recommendations
Ocular Therapeutix analyst commentary  »

Ocular Therapeutix price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CNP

CenterPoint Energy

$26.68

-1.42 (-5.05%)

07:23
11/15/19
11/15
07:23
11/15/19
07:23
Downgrade
CenterPoint Energy rating change  »

CenterPoint Energy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NBLX

Noble Midstream

$22.29

-0.36 (-1.59%)

07:22
11/15/19
11/15
07:22
11/15/19
07:22
Recommendations
Noble Midstream analyst commentary  »

Noble Midstream price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ASB

Associated Banc-Corp

$21.43

-0.08 (-0.37%)

07:22
11/15/19
11/15
07:22
11/15/19
07:22
Conference/Events
Associated Banc-Corpmanagement to meet with Stephens »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

  • 18

    Nov

NVDA

Nvidia

$209.88

1.33 (0.64%)

07:21
11/15/19
11/15
07:21
11/15/19
07:21
Upgrade
Nvidia rating change  »

Nvidia upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 06

    Jan

NCNA

NuCana

$5.59

-0.35 (-5.89%)

07:21
11/15/19
11/15
07:21
11/15/19
07:21
Recommendations
NuCana analyst commentary  »

NuCana price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMRN

Amarin

$21.49

(0.00%)

07:19
11/15/19
11/15
07:19
11/15/19
07:19
Recommendations
Amarin shares could move towards $51 after positive vote, says H.C. Wainwright »

Following the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Dec

FTNT

Fortinet

$100.07

0.38 (0.38%)

07:18
11/15/19
11/15
07:18
11/15/19
07:18
Upgrade
Fortinet rating change  »

Fortinet upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

  • 18

    Nov

  • 19

    Nov

  • 05

    Dec

  • 06

    Dec

  • 09

    Dec

  • 12

    Dec

AMRN

Amarin

$21.49

(0.00%)

07:17
11/15/19
11/15
07:17
11/15/19
07:17
Recommendations
Amarin analyst commentary  »

Amarin shares should…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Dec

07:15
11/15/19
11/15
07:15
11/15/19
07:15
General news
European stock markets moved mostly higher »

European stock markets…

WIX

Wix.com

$125.11

-10.76 (-7.92%)

07:14
11/15/19
11/15
07:14
11/15/19
07:14
Recommendations
Wix.com analyst commentary  »

Wix.com price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

  • 19

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.